Prostate cancer gene 3/prostate specific antigen (PCA3/PSA) mRNA expression IVD, kit, nucleic acid technique (NAT)
United Kingdom·In Vitro Diagnostic Device·Exosome Diagnostics Inc.·Registered Jul 28, 2022- Device ID
- 153043
- MHRA Reference Number
- 153043
- Date Registered
- Jul 28, 2022
- Last Updated
- Dec 22, 2022
- Device Type
- In Vitro Diagnostic Device
- Devices
- Prostate cancer gene 3/prostate specific antigen (PCA3/PSA) mRNA expression IVD, kit, nucleic acid technique (NAT)
- Type
- IVD General
- Address
- 266 Second Ave. Suite 200 Waltham, Massachusetts, United States
- Created Date
- Jul 28, 2022
- Relationship Type
- UK Responsible Person
- Address
- Compass House, Vision Park Histon c/o Cr360 – UL International Cambridge, England, United KingdomPostcode: CB24 9BZ
Devices with a matching generic name or device type registered with MHRA
Additional devices represented by Emergo Consulting (UK) Limited in the UK
Prostate cancer gene 3/prostate specific antigen (PCA3/PSA) mRNA expression IVD, kit, nucleic acid technique (NAT) is a medical device registered with the UK's Medicines and Healthcare products Regulatory Agency (MHRA) under Device ID 153043. The device is manufactured by Exosome Diagnostics Inc. from United States, classified as In Vitro Diagnostic Device. The authorized representative in the UK is Emergo Consulting (UK) Limited .
This page provides comprehensive regulatory information including complete registration details, manufacturer information, device classification, authorized representative details, and related products. Pure Global AI offers free access to 150,962+ UK MHRA medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.